All articles by GlobalData Healthcare

  1. Could PF-06480605 Phase IIb trial registration pave the way for Pfizer’s dominance in UC space?

    On 16 September, Pfizer registered a Phase IIb trial to assess the safety and efficacy of PF-06480605 in adult participants…
    Read More…

    20 Sep
  2. Pfizer’s Phase II results strengthen likely regulatory approval for 20vPnC

    Pfizer’s Phase II results strengthen likely regulatory approval for 20vPnC  On September 9, Pfizer announced positive results for a randomised,…
    Read More…

    20 Sep
  3. Lexicon’s reliance on risk mitigation protocols for type 1 diabetes pursuit for Zynquista elicits mixed reactions

    Lexicon Pharmaceuticals pursuit to get Zynquista (sotagliflozin) approved for type 1 diabetes (T1D) post an FDA Complete Response Letter (CRL)…
    Read More…

    20 Sep
  4. Psilocybin depression therapy faces cost-effectiveness challenges versus J&J’s Spravato

    Despite the potential advantage of psilocybin therapy’s long treatment duration in treatment-resistant depression (TRD) and major depressive disorder (MDD), its…
    Read More…

    20 Sep
  5. Novartis pushes back regulatory filing of Rett syndrome gene therapy

    Novartis has delayed the Investigational New Drug (IND) submission for its Rett syndrome gene therapy, AVXS-201, according to a spokesperson…
    Read More…

    20 Sep
  6. Earlier treatment with Ocrevus reduces permanent disability progression by 42% in MS

    Trial results from Roche’s blockbuster, Ocrevus (ocrelizumab), were presented at the Congress of the European Committee for Treatment and Research…
    Read More…

    20 Sep
  7. New positive data presented for Janssen’s ponesimod remains questionable

    Janssen, a subsidiary of Johnson & Johnson, presented positive top-line results from the Phase III OPTIMUM study at the annual…
    Read More…

    18 Sep
  8. Chasing Cancer considers how to improve patient access to cancer therapies

    A Washington Post live event entitled Chasing Cancer was held in Boston, Massachusetts, US, on 4 September, to consider strategies…
    Read More…

    16 Sep
  9. First-in-class HIF-2a inhibitor could revolutionise renal cell carcinoma treatment algorithm

    Following the acquisition of Peloton Therapeutics in July 2019, Merck is accelerating the development of the first-in-class oral, selective hypoxia-inducible…
    Read More…

    13 Sep
  10. Trial halted early as Nuplazid shows strong efficacy in dementia-related psychosis

    Acadia’s Nuplazid (pimavanserin) has performed so well in Phase III clinical trial that the trial has been halted early. Nuplazid…
    Read More…

    13 Sep
Close
Close
Close

Go Top